145 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
;
the cost of clinical trials of any of our programs may be greater than we anticipate;
the quality of our product candidates or other materials necessary … materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
).
“Hazardous Materials” means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable … and materialmen, to secure claims for labor, materials or supplies.
“Person” means an individual or a corporation, partnership, trust, incorporated
8-K
EX-10.1
pco4 ysf0
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.2
h4dl euemecm2
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
3korckj
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
p8ky4ekia0h6h2a27l4
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
h2hkmwh6
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
m99gpww3i0oke92igf7h
5 Feb 24
Entry into a Material Definitive Agreement
7:36am